問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Taichung Veterans General Hospital

Division of Hematology & Oncology

更新時間：2023-11-06

沈佳儀Shen, Chia-I
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

96Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

沈佳儀

List

124Cases

2022-11-30 - 2027-10-31

Phase III

A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07)

  • Condition/Disease

    Metastatic Non Small Cell Lung Cancer

  • Test Drug

    Datopotamab deruxtecan (Dato-DXd；DS-1062a)

Participate Sites
9Sites

Recruiting9Sites

2022-03-01 - 2028-04-30

Phase III

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

  • Condition/Disease

    Metastatic Non Small Cell Lung Cancer

  • Test Drug

    datopotamab deruxtecan (Dato-DXd; INN: DS-1062a)

Participate Sites
9Sites

Recruiting9Sites

2023-11-01 - 2025-12-31

Phase II

DAREON™-5: An open-label, multi-center Phase II dose selection trial of intravenous BI 764532, a DLL3-targeting T cell engager, in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas

  • Condition/Disease

    Small Cell Lung Carcinoma 、Neuroendocrine Neoplasms

  • Test Drug

    BI 764532

Participate Sites
3Sites

Not yet recruiting3Sites

2023-05-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 9 10 11 12 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB